North America Exosome Diagnostic and Therapeutic Market is expected to reach US$ 154,116.95 thousand by 2027


PRESS RELEASE BY The Insight Partners 29 Apr 2020

Share this press on


Diagnostic Application Segment to Grow at Faster Pace During Forecast Period

 

According to The Insight Partners market research study of "North America Exosome Diagnostic and Therapeutic Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Application, Product, and End User", the North America exosome diagnostic and therapeutic market is projected to reach US$ 154.1 million by2027 from US$ 17.5 million in2019. The market is estimated to grow at CAGR of 32.5% from 2020 to 2027. The report highlights trends prevailing in the North America exosome diagnostic and therapeutic market and the factors driving market along with those that act as hindrances.

 

The North America exosome diagnostic and therapeutic market, based on application, is further segmented into diagnostic and therapeutic. The diagnostic segment held a larger share of the market in 2019. Also, the diagnostic segment is estimated to register a higher CAGR during the forecast period owing to increasing adoption to exosomes for the diagnosis of chronic conditions and increasing awareness of procedural outcomes served by exosomes. Increasing awareness about exosomes diagnostics is propelling the companies to enter into this market to tap lucrative opportunities. For instance, in March 2016, Sysmex and JVCKENWOOD launched a joint program for the development of diagnostic instruments for measurement of exosomes.

 

The North America exosome diagnostic and therapeutic market is expected to grow owing to factors such as greater precision and advantages over traditional methods of diagnosis and therapeutics and increasing number of research activities in the field of exosomes. However, poor infrastructure and lack of expertise required for isolation of exosomes are likely to restrain the growth of the market during the forecast period.

 

Leading companies operating in the exosome diagnostic and therapeutic market are Aethlon Medical, Inc., Therapeutic Solutions International, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, Cell Guidance Systems LLC, BioRegenerative Sciences, Evomic Science LLC, NorgenBiotek Corp., Exosome Diagnostics, Inc./Bio-Techne, and MiltenyiBiotec, among others.

 

North America Exosome Diagnostic and Therapeutic Market, By Country, 2019 (%)


North America Exosome Diagnostic and Therapeutic Market, By Country, 2019 (%)


North America Exosome Diagnostic and Therapeutic Market to Grow at a CAGR of 32.5% to reach US$ 154,116.95 thousand from 2020 to 2027

Download Free Sample

North America Exosome Diagnostic and Therapeutic Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Application (Diagnostic and Therapeutic); Product (Instruments, Reagents, and Software); End User (Cancer Institute, Hospitals, Diagnostic Centers, and Other End Users), and Country

The report segments North America Exosome Diagnostic And Therapeutic Market as follows:

By Application

  • Diagnostic
  • Therapeutic

By Product

  • Instruments
  • Reagents
  • Software

By End User

  • Cancer Institutes
  • Hospitals
  • Diagnostic Centers
  • Others

By Country

  • US
  • Canada
  • Mexico
Contact Us
 
Phone: +1-646-491-9876
Download Free PDF Brochure